Last updated: May 29, 2026

Application No. 18/578,932

NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

Final Rejection

Filed

Aug 22, 2024

Priority

Sep 01, 2021 — JP 2021-142742 +1 more

Examiner

KOSAR, ANDREW D

Art Unit

1625

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Shionogi & Co. Ltd.

OA Round

2 (Final)

This examiner grants 42% of cases after interview

— +31.4% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 259 resolved cases, 2023–2026

Examiner Intelligence

KOSAR, ANDREW D View full profile →

Grants 42% of resolved cases

Career Allowance Rate

109 granted / 259 resolved

-17.9% vs TC avg

Strong +31% interview lift

Without

With

+31.4%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

9 currently pending

Career history

274

Total Applications

across all art units

Statute-Specific Performance

§101

1.0%

-39.0% vs TC avg

§103

34.5%

-5.5% vs TC avg

§102

17.9%

-22.1% vs TC avg

§112

20.1%

-19.9% vs TC avg

Black line = Tech Center average estimate • Based on career data from 259 resolved cases

Prosecution Timeline

Aug 22, 2024

Application Filed

Sep 24, 2025

Non-Final Rejection mailed

Mar 24, 2026

Response Filed

May 20, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/925,854

Patent 12637480

HETEROCYCLIC COMPOUNDS AS STING MODULATORS

3y 6m to grant Granted May 26, 2026

18/673,671

Patent 12606773

IONIZABLE CATIONIC LIPIDS

1y 11m to grant Granted Apr 21, 2026

18/033,317

Patent 12600720

MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY

2y 11m to grant Granted Apr 14, 2026

18/041,540

Patent 12570653

PYRIMIDINE RING COMPOUND

3y 0m to grant Granted Mar 10, 2026

17/925,493

Patent 12552758

INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT

3y 3m to grant Granted Feb 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

42%

Grant Probability

74%

With Interview (+31.4%)

3y 5m (~1y 8m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 259 resolved cases by this examiner. Grant probability derived from career allowance rate.